StockData
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. (MRKR) stock

MRKRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 6/30
$0.84+0.01 (+0.97%)

Close on Nov 17, 2026Market cap $13.95MP/E –Yield –

Marker Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Marker Therapeutics's pe ratio was 1.0× on Oct 31, 2016.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2016Oct 31, 20161.0×–

More Marker Therapeutics figures

See a number that looks wrong?